Evidence map›Paper›PMID 40909962›Full record

ArticleFrontiers in oncology2025

Combined serine protease PRSS22 and CEA mRNA analysis identifies the majority of colon cancer patients that recur within 12 years.

Alaa Mohamed, Manar AbdelMageed, Faten Zahran, Nabila Zein, Lina Olsson, Gudrun Lindmark, Marie-Louise Hammarström, Sten Hammarström, Basel Sitohy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alaa MohamedDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Manar AbdelMageedDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Faten ZahranDepartment of Biochemistry, Faculty of Science, Zagazig University, Zagazig, Egypt.
Nabila ZeinDepartment of Biochemistry, Faculty of Science, Zagazig University, Zagazig, Egypt.
Lina OlssonDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Gudrun LindmarkDepartment of Clinical Sciences, Lund University, Lund, Sweden.
Marie-Louise HammarströmDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Sten HammarströmDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Basel SitohyDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Proteases play an important role in tumor progression. The predictive efficacy of proteases PRSS3 and PRSS22 mRNA levels for predicting relapse in surgically treated colon cancer (CC) patients was assessed. Methods: mRNA expression was quantified in 371 half lymph nodes (LNs) from 121 CC patients, 77 control LNs (13 patients), 66 primary colon tumors, and 30 normal colon tissues of these patients. Patients were also stratified according to their CEA mRNA level. The occurrence of relapse following curative surgery was evaluated using the Cox regression and Kaplan-Meier survival model analyses. Protein expression was examined through immunohistochemistry. Results: PRSS22 was superior to PRSS3 in identifying patients at risk of recurrence. Thus, high PRSS22 levels in LNs identified 76.5% of those who recurred, while PRSS3 only identified 17.6% of these patients and these were in TNM stages III and IV. The Kaplan-Meier analysis indicated that CC patients exhibiting elevated PRSS22 levels in lymph nodes experienced a reduction in survival time, averaging 37 months over the follow-up period ( Conclusion: The importance of the secreted serine protease, S1 family member PRSS22 in tumor progression is highlighted. It shows promise as a biomarker for CC prognosis and as a target to prevent tumor spread by inhibiting its enzymatic activity.

Indexed as

CEAcolon cancermRNA analysisprognosisPRSS22PRSS3regional lymph nodesserine proteases

Identifiers

PMID40909962
PMCPMC12406016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.